Loading
Latest filing published 11 Sept 2023 for NRX Pharmaceuticals, Inc., €18k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Chaim Hurvitz (board member) discloses dealings in NRX Pharmaceuticals, Inc. to SEC (Form 4). Over a trading history stretching from 24 May 2021 to 30 August 2023, the count stands at 4 filings.
Purchases make up the whole of the open-market record (3 purchases, €569k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant. In 2023 alone, the filings show 1 purchase and no sales.
The median purchase comes to €275k.
The latest filing, published on 11 September 2023, reports an open-market purchase of €18k in NRX Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 10 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations